• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

范德比尔特PRS-KS的开发与验证,一种用于量化多基因风险评分知识的工具。

Development and validation of the Vanderbilt PRS-KS, an instrument to quantify polygenic risk score knowledge.

作者信息

Stubbs Doug, Hooker Gillian W, Li Yajing, Richter Lucas, Bick Alexander

机构信息

Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Concert Genetics, Nashville, TN.

出版信息

Genet Med Open. 2023 Jun 1;1(1):100822. doi: 10.1016/j.gimo.2023.100822. eCollection 2023.

DOI:10.1016/j.gimo.2023.100822
PMID:39669253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11613715/
Abstract

PURPOSE

As polygenic risk scores (PRSs) enter clinical practice, health care providers' and the publics' comprehension of PRS results are of great importance; yet, they are poorly understood. We present the Vanderbilt polygenic risk scores knowledge scale (Vanderbilt PRS-KS), a tool to quantify PRS knowledge.

METHODS

The Vanderbilt PRS-KS was developed by a team of genetic counselors and physicians to cover key conceptual facts pertaining to PRSs. We recruited ( = 500) individuals with demographics representative of a U.S. sample and graduate-level health care students ( = 74) at a large academic medical center to participate in this validation study. We evaluated the Vanderbilt PRS-KS's psychometric properties using confirmatory factor analysis and item response theory.

RESULTS

The 7-item Vanderbilt PRS-KS correlated to a single latent construct on confirmatory factor analysis (Λ = 0.31-0.61). The scale showed promising reliability (Cronbach's α = 0.66) with item response theory summed scores of ≥2 to ≤5, demonstrating reliability >0.70. The Vanderbilt PRS-KS significantly correlated with genetic knowledge and applied PRS knowledge (r = 0.55 and r = 0.29), and graduate-level health care students scored significantly higher compared with the U.S. representative sample ( < .01).

CONCLUSION

The Vanderbilt PRS-KS is a rigorously validated measure to quantify PRS knowledge. Clinicians should tailor future PRS knowledge interventions to the identified knowledge gaps, including PRS inheritance, equity of performance in different ethnicities, and integration with other health determinants.

摘要

目的

随着多基因风险评分(PRSs)进入临床实践,医疗保健提供者和公众对PRS结果的理解至关重要;然而,人们对其了解甚少。我们提出了范德比尔特多基因风险评分知识量表(Vanderbilt PRS-KS),这是一种量化PRS知识的工具。

方法

范德比尔特PRS-KS由一组遗传咨询师和医生开发,涵盖与PRSs相关的关键概念性事实。我们招募了500名具有美国样本代表性人口统计学特征的个体以及一所大型学术医疗中心的74名研究生水平的医疗保健专业学生参与这项验证研究。我们使用验证性因子分析和项目反应理论评估了范德比尔特PRS-KS的心理测量特性。

结果

在验证性因子分析中,7项范德比尔特PRS-KS与单一潜在结构相关(Λ = 0.31 - 0.61)。该量表显示出良好的信度(克朗巴哈α系数 = 0.66),项目反应理论总分在≥2至≤5之间,表明信度>0.70。范德比尔特PRS-KS与遗传知识和应用PRS知识显著相关(r = 0.55和r = 0.29),并且研究生水平的医疗保健专业学生的得分显著高于美国代表性样本(P <.01)。

结论

范德比尔特PRS-KS是一种经过严格验证的量化PRS知识的测量工具。临床医生应根据已确定的知识差距调整未来的PRS知识干预措施,包括PRS遗传、不同种族表现的公平性以及与其他健康决定因素的整合。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ef5/11613715/84a1644a9cc8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ef5/11613715/5acf07a1171e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ef5/11613715/90f0c6cf1281/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ef5/11613715/84a1644a9cc8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ef5/11613715/5acf07a1171e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ef5/11613715/90f0c6cf1281/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ef5/11613715/84a1644a9cc8/gr3.jpg

相似文献

1
Development and validation of the Vanderbilt PRS-KS, an instrument to quantify polygenic risk score knowledge.范德比尔特PRS-KS的开发与验证,一种用于量化多基因风险评分知识的工具。
Genet Med Open. 2023 Jun 1;1(1):100822. doi: 10.1016/j.gimo.2023.100822. eCollection 2023.
2
Precision Medicine in Cardiovascular Disease Prevention: Clinical Validation of Multi-Ancestry Polygenic Risk Scores in a U.S. Cohort.心血管疾病预防中的精准医学:美国队列中多血统多基因风险评分的临床验证
Nutrients. 2025 Mar 6;17(5):926. doi: 10.3390/nu17050926.
3
Polygenic risk scores for the prediction of common cancers in East Asians: A population-based prospective cohort study.基于人群的前瞻性队列研究:东亚常见癌症的多基因风险评分预测。
Elife. 2023 Mar 27;12:e82608. doi: 10.7554/eLife.82608.
4
Polygenic Risk, Psychopathology, and Personalized Functional Brain Network Topography in Adolescence.青少年中的多基因风险、精神病理学与个性化功能性脑网络拓扑结构
medRxiv. 2025 Mar 21:2024.09.20.24314007. doi: 10.1101/2024.09.20.24314007.
5
Psychiatric Polygenic Risk Scores Across Youth With Bipolar Disorder, Youth at High Risk for Bipolar Disorder, and Controls.双相情感障碍青少年、双相情感障碍高危青少年及对照组的精神科多基因风险评分
J Am Acad Child Adolesc Psychiatry. 2024 Nov;63(11):1149-1157. doi: 10.1016/j.jaac.2023.12.009. Epub 2024 Feb 8.
6
General . specific vulnerabilities: polygenic risk scores and higher-order psychopathology dimensions in the Adolescent Brain Cognitive Development (ABCD) Study.一般. 特定弱点:青少年大脑认知发展 (ABCD) 研究中的多基因风险评分和高阶精神病理学维度。
Psychol Med. 2023 Apr;53(5):1937-1946. doi: 10.1017/S0033291721003639. Epub 2021 Sep 14.
7
Development and Validation of Peer Relationship Scale for Chinese Community-Dwelling Elderly.中国社区老年人同伴关系量表的编制与验证
Psychol Res Behav Manag. 2021 Jun 28;14:889-903. doi: 10.2147/PRBM.S311352. eCollection 2021.
8
Return of polygenic risk scores in research: Stakeholders' views on the eMERGE-IV study.多基因风险评分在研究中的回归:利益相关者对 eMERGE-IV 研究的看法。
HGG Adv. 2024 Apr 11;5(2):100281. doi: 10.1016/j.xhgg.2024.100281. Epub 2024 Feb 27.
9
Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition.基于遗传祖源构成的乳腺癌多基因风险评分的开发和验证。
JCO Precis Oncol. 2022 Nov;6:e2200084. doi: 10.1200/PO.22.00084.
10
Polygenic Risk Score for Alzheimer's Disease in Caribbean Hispanics.加勒比海西班牙裔人群阿尔茨海默病的多基因风险评分。
Ann Neurol. 2021 Sep;90(3):366-376. doi: 10.1002/ana.26131. Epub 2021 Jun 17.

本文引用的文献

1
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.临床中多基因风险评分的合理使用:潜在的获益、风险和差距。
Nat Med. 2021 Nov;27(11):1876-1884. doi: 10.1038/s41591-021-01549-6. Epub 2021 Nov 15.
2
Why do people seek out polygenic risk scores for complex disorders, and how do they understand and react to results?为什么人们会寻求复杂疾病的多基因风险评分,以及他们如何理解和应对这些结果?
Eur J Hum Genet. 2022 Jan;30(1):81-87. doi: 10.1038/s41431-021-00929-3. Epub 2021 Jul 19.
3
Knowledge, views and expectations for cancer polygenic risk testing in clinical practice: A cross-sectional survey of health professionals.
知识、观点和对临床实践中癌症多基因风险检测的期望:一项对卫生专业人员的横断面调查。
Clin Genet. 2021 Oct;100(4):430-439. doi: 10.1111/cge.14025. Epub 2021 Jul 12.
4
Improving reporting standards for polygenic scores in risk prediction studies.提高风险预测研究中多基因评分报告标准。
Nature. 2021 Mar;591(7849):211-219. doi: 10.1038/s41586-021-03243-6. Epub 2021 Mar 10.
5
Exploration of experiences with and understanding of polygenic risk scores for bipolar disorder.双相情感障碍多基因风险评分的经验探索与理解
J Affect Disord. 2020 Mar 15;265:342-350. doi: 10.1016/j.jad.2020.01.037. Epub 2020 Jan 13.
6
Uptake of polygenic risk information among women at increased risk of breast cancer.具有乳腺癌风险升高的女性对多基因风险信息的接受情况。
Clin Genet. 2020 Mar;97(3):492-501. doi: 10.1111/cge.13687. Epub 2019 Dec 25.
7
The REDCap consortium: Building an international community of software platform partners.REDCap 联盟:构建软件平台合作伙伴的国际社区。
J Biomed Inform. 2019 Jul;95:103208. doi: 10.1016/j.jbi.2019.103208. Epub 2019 May 9.
8
What Are Polygenic Scores and Why Are They Important?多基因评分是什么,为什么它们很重要?
JAMA. 2019 May 14;321(18):1820-1821. doi: 10.1001/jama.2019.3893.
9
Clinical use of current polygenic risk scores may exacerbate health disparities.现行多基因风险评分的临床应用可能会加剧健康差异。
Nat Genet. 2019 Apr;51(4):584-591. doi: 10.1038/s41588-019-0379-x. Epub 2019 Mar 29.
10
Development of the Knowledge of Genome Sequencing (KOGS) questionnaire.基因组测序知识(KOGS)问卷的编制。
Patient Educ Couns. 2018 Nov;101(11):1966-1972. doi: 10.1016/j.pec.2018.07.011. Epub 2018 Jul 11.